Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ADRB3 | P13945 | 8/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4716146 | 0.99 | KMT2A (0.51) | KMT2AADRB3ADRB1ADRB2SLC2A1 | |
| SCHEMBL19329740 | 0.87 | ADRB3 (0.53) | ADRB3ADRB1ADRB2LMNA | |
| SCHEMBL7906262 | 0.86 | OPRM1 (0.49) | ADRB3ADRB1ADRB2SLC2A1EPHX2 | |
| SCHEMBL9191899 | 0.82 | ALDH1A1 (0.55) | LMNA | |
| SCHEMBL13849930 | 0.81 | ADRB1 (0.48) | ADRB3ADRB1ADRB2SLC2A1LMNA | |
| SCHEMBL6690481 | 0.81 | ADRB1 (0.48) | ADRB3ADRB1ADRB2SLC2A1LMNA | |
| SCHEMBL13849942 | 0.81 | ADRB1 (0.48) | ADRB3ADRB1ADRB2SLC2A1LMNA | |
| SCHEMBL14402491 | 0.81 | ADRB1 (0.48) | ADRB3ADRB1ADRB2SLC2A1LMNA | |
| SCHEMBL24302767 | 0.80 | SLC6A4 (0.54) | ADRB3ADRB1ADRB2SLC2A1LMNA | |
| SCHEMBL5848672 | 0.78 | ADRB3 (0.55) | ADRB3ADRB1ADRB2SLC2A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1993524-A1 | THE USE OF BUPROPION METABOLITES FOR THE TREATMENT OF INFLAMMATORY DISORDERS | Sosei R&D Ltd. (GB) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007102019-A1 | THE USE OF BUPROPION METABOLITES FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SOSEI R & D LTD. (GB) | 2007-09-13 | — | — | WO | disclosed |